Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 6, 2013, Pages 687-688

  Da Silva, Elizabeth Nicole ^a,b   Randall, Katrina Louise ^a,b  

^a CANBERRA HOSPITAL   (Australia)

^b The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BEE VENOM; IMMUNOGLOBULIN E; OMALIZUMAB; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AFFECT; AGITATION; ALLERGY; ANAPHYLAXIS; ARTICLE; BEE STING; BEHAVIOR CHANGE; BLOOD PRESSURE; CASE REPORT; DYSPNEA; FLUSHING; GENE MUTATION; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; IRRITABILITY; MALE; MASTOCYTOSIS; PEAK EXPIRATORY FLOW; SIDE EFFECT; UNCONSCIOUSNESS; VERBAL HOSTILITY; VISUAL IMPAIRMENT; VOMITING; INSECT BITES AND STINGS; MIDDLE AGED; PROCEDURES;

ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BEE VENOMS; HUMANS; IMMUNOTHERAPY; INSECT BITES AND STINGS; MALE; MASTOCYTOSIS; MIDDLE AGED;

EID: 84887017741     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.07.004     Document Type: Article

References (11)

1. Krishna M.T., Ewan P.W., Diwakar L., Durham S.R., Frew A.J., Leech S.C., et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy 2011, 41:1201-1220.
2. Bonadonna P., Perbellini O., Passalacqua G., Caruso B., Colarossi S., Dal Fior D., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123:680-686.
3. Oude Elberink J.N.G., de Monchy J.G.R., Kors J.W., van Doormaal J.J., Dubois A.E.J. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. JAllergy Clin Immunol 1997, 99:153-154.
4. Rueff F., Przybilla B., Biló M.B., Müller U., Scheipl F., Aberer W., et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase. JAllergy Clin Immunol 2010, 126:105-111.
5. Galera C., Soohun N., Zankar N., Caimmi S., Gallen C., Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. JInvestig Allergol Clin Immunol 2009, 19:225-229.
6. Schulze J., Rose M., Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007, 62:963-964.
7. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008, 63:376-378.
8. Kontou-Fili K., Filis C.I. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009, 64:1384-1392.
9. Soriano Gomis V., Gonzalez Delgado P., Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. JInvestig Allergol Clin Immunol 2008, 18:225-226.
10. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. JAllergy Clin Immunol 2004, 114:527-530.
11. Kontou-Fili K., Filis C.I., Voulgari C., Panayiotidis P.G. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 2010, 104:537-539.